COLL Earnings & Financial Statements
Collegium Pharmaceutical, Inc.
$22.51
+$0.98(+4.55%)
52
Overall
75
Value
18
Tech
63
Quality
Market Cap
$732.83M
Volume
920.24K
52W Range
$21.43 - $50.79
Target Price
$49.00
COLL earnings and financial statements: Collegium Pharmaceutical, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
COLL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $780.57M | $631.45M | $566.77M | $463.93M | $276.87M |
| Cost of revenue | $95.42M | $88.80M | $94.84M | $118.19M | $59.07M |
| Operating income | $179.64M | $169.90M | $166.96M | $33.32M | $17.63M |
| EBITDA | $406.35M | $347.72M | $171.20M | $181.59M | $89.96M |
| Net income | $62.87M | $69.19M | $48.16M | -$25.00M | $71.52M |
| EPS (diluted) | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.08M |
| Total liabilities | $1.36B | $1.43B | $947.88M | $979.29M | $489.15M |
| Shareholders’ equity | $301.68M | $228.84M | $195.43M | $194.84M | $202.93M |
| Cash and equivalents | $231.25M | $70.56M | $238.95M | $173.69M | $186.43M |
| Long-term debt | $784.46M | $793.44M | $489.96M | $545.56M | $209.58M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $329.32M | $204.98M | $274.75M | $124.23M | $103.56M |
| Capital expenditure | -$1.74M | -$1.65M | -$461.0K | -$1.62M | -$1.94M |
| Free cash flow | $327.58M | $203.33M | $274.29M | $122.61M | $101.61M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | COLL | $22.51 | +4.6% | 920.24K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Collegium Pharmaceutical, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW